<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802317</url>
  </required_header>
  <id_info>
    <org_study_id>03-08/20</org_study_id>
    <nct_id>NCT04802317</nct_id>
  </id_info>
  <brief_title>Intestinal Microbiota in COPD and Asthma</brief_title>
  <acronym>MicrObAs</acronym>
  <official_title>Identifying the Relationship Between the Features of the Composition and Functioning of the Intestinal Microbiota With the Course of Chronic Obstructive Pulmonary Disease and Asthma (MicrObAs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Research Center for Therapy and Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Strategic Planning and Management of Biomedical Health Risks</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Medical Research Center for Therapy and Preventive Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The composition of the intestinal microbiota, the level of lipopolysaccharides, TMAO in the&#xD;
      blood, and other parameters of patients with COPD (n=50), asthma (n=50) and the control&#xD;
      (n=40) will be assessed as factors associated with exacerbations and respiratory symptoms in&#xD;
      the prospective study (12 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients from &quot;Biobank of blood and feces for the development of a clinical and&#xD;
      biological platform as a basis for an innovative approach to the prevention of chronic&#xD;
      non-infectious diseases based on the composition of the intestinal microbiota&quot; study will be&#xD;
      included (cross-sectional study). The protocol of the above study included the assessment of&#xD;
      socio-demographic, anthropometric data, clinical blood pressure (BP), ECG, blood tests, fecal&#xD;
      microbiota studies, spirometry data, diet questionnaire. ABPM, HBP, other questionnaires&#xD;
      (mMRC, CAT, ACQ-5, GMBQ) will be added to initial data (=visit 1). Than the four visits&#xD;
      (2-5th visits) in 3 each months will be performed to assess respiratory symptoms,&#xD;
      exacerbations of COPD/asthma, respiratory infections, therapy, BP, and other parameters. The&#xD;
      standard statistical methods will be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exacerbation of asthma / chronic obstructive pulmonary disease</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with exacerbation of bronchial asthma or chronic obstructive pulmonary disease, number of exacerbation per year</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Chronic Respiratory Diseases</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Health people without any respiratory diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bronchial asthma</arm_group_label>
    <description>Patients with asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <description>Patients with chronic obstructive pulmonary disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Identification of the composition of the intestinal microbiota</intervention_name>
    <description>Identification of the composition of the intestinal microbiota</description>
    <arm_group_label>Bronchial asthma</arm_group_label>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients without COPD, asthma, chronic bronchitis and other lung diseases for control&#xD;
        group. Patients asthma/COPD with for asthma/COPD groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        for control group:&#xD;
&#xD;
          -  Normal spirometry results with bronchodilation test (salbutamol 400 mcg);&#xD;
&#xD;
          -  Absence of COPD, asthma, chronic bronchitis and other lung diseases&#xD;
&#xD;
          -  BMI&lt;40kg/m2&#xD;
&#xD;
        for asthma/COPD groups:&#xD;
&#xD;
          -  Primary medical documentation confirming the diagnosis of COPD or asthma&#xD;
&#xD;
          -  Regular therapy for COPD, asthma and any chronic disease for at least 4 weeks prior to&#xD;
             enrollment in this study.&#xD;
&#xD;
          -  FEV1 / FVC &lt;0.70 after inhalation of 400 mcg of salbutamol for patients with COPD&#xD;
&#xD;
          -  BMI&lt;40kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exacerbation of chronic noninfectious diseases, including exacerbation of COPD /&#xD;
             asthma, within 4 weeks prior to enrollment in this study.&#xD;
&#xD;
          -  Exacerbation of COPD or asthma in the next 3 months, requiring the treatment of&#xD;
             antibiotic therapy or systemic corticosteroids;&#xD;
&#xD;
          -  Cerebral stroke, transient ischemic attack or myocardial infarction within 6 months&#xD;
             before the date of enrollment in the study;&#xD;
&#xD;
          -  Clinically significant chronic diseases (oncological, systemic diseases of the&#xD;
             connective tissue, diseases of the blood system, heart failure, Crohn's disease,&#xD;
             ulcerative colitis, etc. according to anamnesis);&#xD;
&#xD;
          -  GFR &lt;30 ml / min / 1.73m2;&#xD;
&#xD;
          -  Atopy in a patient with COPD or a control group (any allergic manifestations - skin,&#xD;
             nasal, conjunctival, food, etc.);&#xD;
&#xD;
          -  Chronic respiratory diseases in a patient of the control group (COPD, asthma, chronic&#xD;
             bronchitis, interstitial lung diseases);&#xD;
&#xD;
          -  History of organ transplantation;&#xD;
&#xD;
          -  Mental illness;&#xD;
&#xD;
          -  Intestinal infection (food poisoning) in the next 3 months;&#xD;
&#xD;
          -  Other acute infectious diseases. It is possible to turn on not earlier than 4 weeks&#xD;
             after complete recovery and cessation of treatment;&#xD;
&#xD;
          -  History of severe COVID-19;&#xD;
&#xD;
          -  HIV infection, chronic viral hepatitis according to the history;&#xD;
&#xD;
          -  Clinically significant oncological disease;&#xD;
&#xD;
          -  Pregnancy and lactation;&#xD;
&#xD;
          -  Alcoholism, taking narcotic drugs;&#xD;
&#xD;
          -  Taking antimicrobial, probiotic drugs and systemic corticosteroids during the last 3&#xD;
             months;&#xD;
&#xD;
          -  Genetic engineering / biological therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Smirnova, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRCPM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina Smirnova, PhD, MD</last_name>
    <phone>+79161168325</phone>
    <email>MSmirnova@gnicpm.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yana Koshelyaevskaya, MSc</last_name>
    <phone>+79153324504</phone>
    <email>YKoshelyaevskaya@gnicpm.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NRCPM</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Smirnova, PhD, MD</last_name>
      <phone>+79161168325</phone>
      <email>MSmirnova@gnicpm.ru</email>
    </contact>
    <contact_backup>
      <last_name>Yana Koshelyaevskaya, MS—Å</last_name>
      <phone>+79153324507</phone>
      <email>YKoshelyaevskaya@gnicpm.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intestinal microbiota</keyword>
  <keyword>COPD</keyword>
  <keyword>asthma</keyword>
  <keyword>lipopolysaccharides</keyword>
  <keyword>trimethylamine-N-oxide</keyword>
  <keyword>course of the diseases</keyword>
  <keyword>exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

